Research programme: G-protein-coupled bile acid receptor-1 agonists - Venenum Biodesign
Latest Information Update: 28 Apr 2022
Price :
$50 *
At a glance
- Originator VENENUM Biodesign
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action GPBAR1 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
- 22 Mar 2018 Preclinical trials in Type-2 diabetes mellitus in USA (PO) before March 2018 (Venenum Biodesign pipeline, March 2018)